Rally Foundation Awards $1M in Grants to Celebrate 20 Years of Advancing Research and Driving Discoveries

In 2026, Rally Foundation for Childhood Cancer Research is thrilled to award $1 million in 20/20 Alumni Visionary Grants to 10 researchers across 9 U.S. institutions.

For 20 years, Rally Foundation has proudly supported groundbreaking ideas, empowered early career investigators and accelerated the path from bench to bedside.

To recognize Rally’s continued role as philanthropic seed investors in the next great discovery, Rally Foundation launched our 20/20: Alumni Visionary Grant. This one-time, competitive grant program honors our past by reinvesting in the exceptional researchers and projects we’ve supported over the years — and empowers the next chapter of discovery.

Meet our 20/20: Alumni Visionary Grant recipients:

• The University of Michigan: Mark Chiang, M.D., Ph.D., for Targeting Newly Defined Pediatric ETP Leukemia with MYB Splicing Inhibitors
• Fred Hutchinson Cancer Center: Eric Chow, M.D., for Enhancing Cardiomyopathy Identification in Cancer Survivors
• Johns Hopkins University School of Medicine: Robyn Gartrell, M.D., for Effect of Radiation Dose Rate on Epigenetic and Immune Response in DMG
• Massachusetts General Hospital: David Langenau, Ph.D., for Therapeutic Targeting of Rhabdomyosarcoma
• Albert Einstein College of Medicine: David Loeb, M.D., Ph.D., for Targeting Arginine Metabolism to Treat Ewing Sarcoma
• The University of California, San Francisco: Amanda Marinoff, M.D., for Accelerating Translation: Risk and Resistance Biomarkers in Osteosarcoma
• Augusta University: David Munn, M.D., for Creating de novo Checkpoint Responsiveness in Pediatric Brain Tumors
• The University of Michigan: John Prensner, M.D., Ph.D., for Defining a Clinical Path for the Dark Proteome in Medulloblastoma
• Emory University: Renee Read, Ph.D., for Synergizing Innate and Adaptive Immunity for High Grade Glioma Therapy
• Baylor College of Medicine: Tamra Werbowetski-Ogilvie, Ph.D., for Identifying New Therapeutic Targets for Group 3 Medulloblastoma Metastasis